B-ALL cells transduced with any of the RUNX1-targeting shRNAs showed greatly reduced proliferative capacity compared to non-targeting control, while the t(9;22) CML cell line K562 was unaffected, consistent with previous reports43. This evidence concerns the gene RUNX1 and acute lymphoblastic leukemia.